Company Performance Metrics
Mervyn Thomas: Co-Founder and Bioinformatics & Regulatory Affairs Director
Stefan Hendriks: Chief Financial Officer & Internal Legal Counsel
Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders. It focuses on the early detection and management of sepsis patients; and the early identification of sepsis in patients at risk. The company engages in the discovery and clinical validation of genomic and proteomic biomarkers; and
the translation of these biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care. It develops SeptiCyte gene expression products, including SeptiCyte Triage for use in emergency and intensive care units (ICUs) or upon hospital admission as a screening tool to diagnose sepsis from other forms of systemic inflammation in adult patients; SeptiCyte STAT for use in ICUs and post-operative wards to monitor and detect sepsis at the earliest possible time in patients who are at high-risk of developing sepsis; and SeptiCyte RTT, a tool for monitoring ICU patients with sepsis to determine the patient’s immune status and the response of their immune system to therapy. The company was formerly known as Athlomics Pty Ltd and changed its name to Immunexpress Pty Ltd in 2011. Immunexpress Pty Ltd was founded in 2006 and is based in Brisbane, Australia with an additional office in Seattle, Washington.
